Beth RogozinskiCEO at Oncoustics
Beth Rogozinski, CEO, Oncoustics Beth Rogozinski is CEO at Oncoustics, an innovative AI diagnostics company that is creating low cost, non-invasive solutions for the detection and surveillance for diseases of the liver, kidney and pancreas. As a serial entrepreneur, technology professional, and business strategist, Beth has produced and published more than a dozen products for health and wellness. As Chief Product Officer at Pear Therapeutics, she led the development of Pear’s first clinical products and the product team submission of the De Novo 510k to the FDA. Pear’s ReSET™ was cleared by the FDA in 2017 as the first ever prescription digital therapeutic. Beth is an advisor to many start-ups and accelerators and has consulted with international biopharma and venture groups around digital health investments. Beth is an advisor and mentor in the UCSF Health Hub, at Columbia’s HIT Lab and has written and published on digital therapeutics and tech innovations. She is excited to bring to life AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need.